APPY News Alert Aspenbio Pharma (APPY) 1.68 12/17/2014 02:11

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aspenbio Pharma (APPY) 1.68 $APPY

Venaxis Files Response to FDA's Request for Additional Information
PR Newswire - Wed Dec 03, 3:35PM CST
Venaxis®, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood-based test designed to aid emergency room clinicians in identifying children, adolescent, and young adult patients who are at low risk for appendicitis, today announced it has filed its response to the FDA's Additional Information (AI) request related to the Company's APPY1 direct de novo submission. Venaxis will provide a business update, including discussion on the APPY1 FDA submission, on Monday, December 8, 2014, at 4:30 p.m. ET. The conference call will be hosted by Steve Lundy, President and CEO.
APPY: 1.68 (+0.02)

Venaxis, Inc. (APPY) in Focus: Stock Adds 7.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 8:32AM CST
Venaxis, Inc. (APPY) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
ICUI: 80.40 (+0.08), GWPH: 67.64 (-0.49), APPY: 1.68 (+0.02), OSUR: 9.10 (unch)

Venaxis to Present at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum
PR Newswire - Thu Nov 13, 3:15PM CST
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced it will be presenting at the Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum being held in New York on November 20, 2014.
APPY: 1.68 (+0.02)

Venaxis: Latest Clinical Data Reveals Huge Market Potential
Blair O'Neill - Seeking Alpha - Wed Oct 29, 10:48AM CDT
Introduction The APPY1 test is a 20 minute diagnostic tool that can be used to rule out the presence of acute appendicitis for the expected price of $80. Venaxis' ( APPY ) goal for the APPY1 test is to reduce the number of CT scans, the use of...
APPY: 1.68 (+0.02)

Venaxis' APPY1 Trial Results Presented by Dr. David S. Huckins, M.D., at ACEP14
PR Newswire - Mon Oct 27, 3:30PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low probability for appendicitis, today announced the company's pivotal APPY1 Test clinical trial data were presented at the American College of Emergency Physicians Scientific Assembly 2014 (ACEP14). The clinical trial involved 29 U.S. hospital sites recruiting patients aged 2 - 20 from January 2013 through January 2014. Results were presented by Lead Principal Investigator Dr. David S. Huckins, M.D.
APPY: 1.68 (+0.02)

Venaxis Announces APPY1 Test Clinical Trial Results to be Presented at ACEP14
PR Newswire - Tue Oct 14, 3:05PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low probability for appendicitis, today announced that results of the company's pivotal APPY1 clinical trial will be presented by Dr. David S. Huckins, M.D., Lead Principal Investigator, at the American College of Emergency Physicians Scientific Assembly 2014 (ACEP14).
APPY: 1.68 (+0.02)

Venaxis to Present at September Investor Conferences
PR Newswire - Thu Aug 28, 8:15AM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced it will present at three upcoming investor conferences: the Rodman & Renshaw 16th Annual Global Investment Conference being held in New York on September 8-10, 2014, the Aegis Capital 2014 Healthcare & Technology Conference being held in Las Vegas on September 10-13, 2014, and the 5th Annual Craig-Hallum Alpha Select Conference being held in New York on September 18, 2014.
APPY: 1.68 (+0.02)

Venaxis to Provide Business Update, including FDA Submission Update
PR Newswire - Thu Aug 07, 3:15PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis, today announced it will provide a business update, including discussion on the progress of the APPY1 FDA submission, on Monday, August 11, 2014, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, President and CEO.
APPY: 1.68 (+0.02)

Venaxis to Present at Canaccord Genuity 34th Annual Growth Conference
PR Newswire - Tue Aug 05, 3:15PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1(TM) Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis, today announced it will present at the Canaccord Genuity 34th Annual Growth Conference, to be held August 13-14, 2014, at the Intercontinental Boston in Boston, MA.
APPY: 1.68 (+0.02)

AspenBio Pharma Down 15.9%, Shares Slide into the Red (APPY)
Comtex SmarTrend(R) - Wed Jul 16, 10:07AM CDT
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 15.9% to $1.88 on 6.3x average daily volume. AspenBio Pharma has traded 1.3 million shares thus far today, vs. average volume of 206,000 shares per day. The stock has underperformed the Dow (-15.9% to the Dow's 0.2%) and underperformed the S&P 500 (-15.9% to the S&P's 0.2%) during today's trading.
APPY: 1.68 (+0.02)

Venaxis Reports on Recent FDA Submission Activities
PR Newswire - Wed Jul 16, 8:15AM CDT
CASTLE ROCK, Colo., July 16, 2014 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis, updated on recent activities concerning its U. S. Food and Drug Administration (FDA) submission for the APPY1 Test that was filed in March 2014. The FDA has reviewed the submission, and provided Venaxis with questions and information requests on the submission.
APPY: 1.68 (+0.02)

Venaxis to Present at ICV Company Outreach Summit
PR Newswire - Tue Jul 01, 3:10PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will participate in the third annual ICV Company Outreach Summit, being held July 9-10, 2014, in Montauk, New York. Steve Lundy, President and CEO of Venaxis® will be presenting at the conference to investors including representatives from hedge and private equity funds as well as high net worth individuals and family funds.
APPY: 1.68 (+0.02)

REMINDER/Media Advisory: Parliamentary Secretary Block to Highlight Government Investments in Clean Energy
Marketwire Canada - Wed Feb 26, 5:00AM CST
Parliamentary Secretary Kelly Block, on behalf of the Honourable Joe Oliver, Canada's Minister of Natural Resources, will deliver remarks about the Government of Canada's investments in clean energy during an event to mark Let's Talk Energy Week at the Museum of Science and Technology.
CBI: 37.78 (-0.52), ARLP: 40.21 (+0.57), ALOG: 82.13 (-0.55), BJRI: 46.84 (-0.23), CENTA: 8.52 (+0.05), APPY: 1.68 (+0.02)

NBA Legend and Business Leader Magic Johnson Shares Empowerment Message as Part of Black History Month
PR Newswire - Tue Feb 11, 11:08AM CST
Earvin "Magic" Johnson is speaking at several events on Allstate's Northbrook, Ill campus discussing the role of education in his life, including the importance of staying in school, and the story of his transformation from athlete to business leader.
APPY: 1.68 (+0.02), ALL: 67.21 (-0.16)

Analysis of the LED Lighting Market in the GCC
PR Newswire - Tue Feb 04, 7:42AM CST
Reportbuyer.com just published a new market research report:
APPY: 1.68 (+0.02)

Venaxis Completes Patient Enrollment in Pivotal Clinical Trial of APPY1(TM) Test
PR Newswire - Fri Jan 24, 6:33AM CST
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced completion of patient enrollment in its pivotal clinical study of the APPY1 Test in the United States. Venaxis expects to announce top-line data following the required patient follow-up period and subsequent database lock and required analysis of the data. The study enrolled patients at approximately 27 hospital sites across the United States, and the pivotal data will be based on approximately 2,000 net evaluable patients.
MDT: 71.34 (-0.65), SIMG: 6.63 (-0.11), MWW: 4.15 (-0.07), APPY: 1.68 (+0.02), NYT: 13.14 (+0.14), AAPL: 106.75 (-1.47), RFMD: 14.94 (+0.01), LF: 4.62 (+0.04)

Spinnaker Support Achieves Record Results and Market Traction in 2013
PR Newswire - Thu Jan 23, 6:00AM CST
Spinnaker Support, a global market leader for SAP, JD Edwards, and Siebel third-party maintenance, application/technical management services, and consulting, today announced a year of tremendous growth as a result of its record-breaking sales and market share gains.
APPY: 1.68 (+0.02)

Social Media Marketing University Announces Its December 2013 Master Certification Program Graduates
PR Newswire - Wed Jan 15, 7:30AM CST
Social Media Marketing University (SMMU) announced today that 8 students received their Master Certification in December. Each student was required to take six core courses and two electives, and pass the program exam. Students have up to one year to complete the program.
APPY: 1.68 (+0.02)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 110

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 93

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 167

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 118

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 162

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 165

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 205

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 87

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 126

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 136

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading

Top 5 Most Recently Viewed Articles

Avaline's Organic Wines Shine in New Holiday Campaign

Updated Category News Views 250

Avaline Unveils Its Charming Holiday Campaign The organic wine brand Avaline is excited to kick off its holiday campaign, which beautifully captures the spirit of the season. By blending nostalgia with festive cheer, Avaline invites everyone to relish the little moments that make the holidays special. The campaign draws inspiration from beloved holiday films, reminding us...

Continue Reading
Exploring In-Game Advertising: Key Insights for Brands

Updated Category News Views 206

Unlocking the Potential of In-Game Advertising Recent research conducted by Cint sheds light on the rising value of in-game advertising (IGA) for brands and the necessity for measurement standards within this dynamic marketing field. Video games have increasingly become a vital platform for advertisers, offering rich engagement opportunities. Consumers are showing...

Continue Reading
Mawson Infrastructure Reports Significant Operational Growth

Updated Category News Views 66

Update on Mawson Infrastructure Group's Operations Mawson Infrastructure Group Inc. recently released a significant operational update that highlights impressive growth in its digital colocation sector. The figures show a remarkable 166% increase in digital colocation revenue compared to a year ago, specifically in August 2023, and a solid 25% growth from the previous...

Continue Reading
Cybersecurity Landscape Evolves: New Threats and Insights

Updated Category News Views 292

An Overview of Current Cybersecurity Threats The digital landscape is becoming increasingly complex, and organizations are challenged with new and emerging cybersecurity threats. Red Canary's recent report dives deep into these threats, highlighting alarming trends that security teams must address now. The Rise of Identity Attacks As technology continues to advance, so do...

Continue Reading
US Family Health Plan Brighton Marine Celebrates Recognition with Awards

Updated Category News Views 188

US Family Health Plan Brighton Marine Honored with Excellence Awards Recent accolades reflect the dedication and quality of care provided by US Family Health Plan Brighton Marine. This esteemed organization has been awarded three Human Experience Pinnacle of Excellence Awards, recognizing it as one of the top health plans across the nation. Such recognition highlights the...

Continue Reading